Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business

Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business

Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company's previously announced merger with Treeline Biosciences, Inc. ("Treeline") and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC.

"We are pleased with the outcome of today's vote and thank our stockholders for their support of these transactions," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership. We look forward to completing both transactions."

The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of remaining customary closing conditions. The sale of the Mass Cytometry business is expected to close substantially concurrently with the Treeline merger.

About Standard BioTools Inc.
Standard BioTools Inc. (NASDAQ: LAB) is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of the merger and the sale of the Mass Cytometry business. The words "will," "toward," "look forward," "planned," "position," "expected," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) risks associated with the possible failure to satisfy the conditions to the closing or consummation of the merger and the sale of the Mass Cytometry business; (ii) risks associated with the uncertainty as to the timing of the consummation of the merger and the sale of the Mass Cytometry business and the ability of each of Standard BioTools and Treeline to consummate the transactions contemplated by the merger agreement; (iii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger and the sale of the Mass Cytometry business prior to the closing or consummation of each; (iv) risks associated with the possible failure to realize certain anticipated benefits of the merger and the sale of the Mass Cytometry business, including with respect to future financial and operating results; (v) the effect of the completion of the merger and the sale of the Mass Cytometry business on the combined company's business relationships, operating results and business generally; and (vi) the risk that the parties may assume unexpected liabilities and expenses as a result of the merger and the sale of the Mass Cytometry business. For information regarding other related risks, see the "Risk Factors" section of Standard BioTools' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 16, 2026, Standard BioTools' subsequent Quarterly Reports on Form 10-Q, Standard BioTools' Form S-4 Registration Statement relating to the merger with Treeline and Standard BioTools' other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.

IR:
ir@standardbio.com

Media:
Dan Moore / Nick Lamplough / David Feldman
Collected Strategies
LAB-CS@collectedstrategies.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LAB
The Conversation (0)
Cerrado Gold Announces Third Quarter 2026 Financial Results

Cerrado Gold Announces Third Quarter 2026 Financial Results

Highlights: Gold equivalent production of 16,985 Gold Equivalent Ounces ("GEO") at AISC of $1,546/oz Au during Q3 2026; Adjusted EBITDA of $33.8 million for Q3 2026 and $90.8 million year-to-date Earnings of US$0.04 per basic share outstanding in Q3 2026 and US$0.16 per share Year to Date,... Keep Reading...
America May Be Sitting on a Gold and Silver Fortune Hiding in Plain Sight

America May Be Sitting on a Gold and Silver Fortune Hiding in Plain Sight

MiningNewsWire Editorial Coverage: With U.S. debt climbing above 100% of GDP while central banks are still accumulating gold, investors are once again seeking safety in silver and gold. Zinc, lead, copper and silver, meanwhile, all now appear on the 2025 List of Critical Minerals published by... Keep Reading...
Renforth Completes Updated Mineral Resource Estimate On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

Renforth Completes Updated Mineral Resource Estimate On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

(TheNewswire) TORONTO, Ontario — November 18, 2026 TheNewswire — Renforth Resources Inc. (CSE: RFR,OTC:RFHRF | OTC: RFHRF | FSE: 9RR) ("Renforth" or the "Company") is pleased to advise shareholders that P&E Mining Consultants Inc. ("P&E") have completed an updated Mineral Resource Estimate... Keep Reading...
Lahontan Receives Final Drill Results For Santa Fe Heap Leach Pad Two, Confirming Gold And Silver Grades

Lahontan Receives Final Drill Results For Santa Fe Heap Leach Pad Two, Confirming Gold And Silver Grades

Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF, OTCQB:LGCXF, FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce results from 16 additional drill holes from its 2026 Sonic core drilling program at the Santa Fe Mine Project. The 16 drill holes reported below, coupled with ten previously... Keep Reading...
Standard Uranium Confirms Uranium and Rare Earth Element Enrichment in Winter Drilling at the Rocas Project

Standard Uranium Confirms Uranium and Rare Earth Element Enrichment in Winter Drilling at the Rocas Project

Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to report a summary of geochemical assay results from its winter 2026 drill program at the Rocas Uranium Project ("Rocas", or the "Project") located 75 kilometers southwest of the Key... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 5 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here, the Investing News Network profiles the five best-performing Canadian biotech stocks... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of November 4, the index stood at 7,463.68, up over 30 percent year-to-date. The rise shows that investors are... Keep Reading...
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or... Keep Reading...
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

(TheNewswire) Third pharmaceutical company relationship entered Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an... Keep Reading...
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

Four presentations highlight BriaCell's Bria-OTS+™ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programsIn vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer modelsBriaPro data describes BP-80... Keep Reading...

Interactive Chart

Latest Press Releases

Related News